madman
Super Moderator
In this episode, I’m joined by Shaun Noorian—engineer, entrepreneur, and CEO of Empower Pharmacy, the largest compounding pharmacy in the world. With compounded GLP-1s making headlines and lawsuits from Big Pharma intensifying, Shaun joins me to pull back the curtain on the regulatory, financial, and ethical storm brewing behind the scenes.
Are compounded GLP-1s legal?
Safe?
Who controls drug pricing in the U.S., and why are Americans paying 10x more than Europeans for the same medication?
And most importantly—what does all this mean for access, affordability, and patient care?
This episode is a wake-up call. If you care about transparency in medicine, patient rights, or access to life-saving medications, don’t miss this one.
We cover:
- Why compounded GLP-1s are under attack—and what the FDA’s recent moves really means
- How Big Pharma sets drug prices—and why Americans pay up to 10x more than other countries
- The legal battle over semaglutide, regulatory capture, and the influence of pharmaceutical lobbying
- How compounding pharmacies offer personalized care and expand access to life-saving medications
- What’s next for patients, clinicians, and the future of affordable medicine in the U.S.
Timestamps:
00:00 – Introduction: Why compounded GLP-1s are in the crosshairs
03:45 – Drug shortages, compounding access, and the rise of semaglutide
08:30 – Why patients flock to compounded medications (and who’s trying to stop it)
12:10 – Eli Lilly lawsuit and Big Pharma’s monopoly playbook
17:05 – Price fixing, international pricing gaps, and the $500/month illusion
21:40 – Regulatory capture: How the FDA, pharma, and lobbying intertwine
26:30 – What compounding pharmacies actually do—and why safety concerns are overblown
30:15 – The April Fool’s FDA warning letters: coincidence or coordinated attack?
35:50 – Can personalized medicine really be considered “dangerous”?
41:00 – What the media gets wrong—and how pharma shapes the narrative
47:00 – Are compounded GLP-1s banned? Sorting fact from fiction
53:25 – What’s next: state-level restrictions, 503B regulations, and the future of patient care
